leadf
logo-loader
viewBioasis Technologies Inc.

Bioasis Technologies secures US patent for its xB3 blood-brain barrier drug delivery platform

The xB3 method utilizes Bioasis’ novel platform technology to administer a broad array of therapeutic agents to the brain tissue in patients who can benefit from this targeted delivery

Patented stamp
Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing compounds into the brain

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) announced Tuesday that the US Patent and Trademark Office (USPTO) issued a patent for the company’s xB3 platform technology, which is designed to deliver therapeutics across the blood-brain barrier (BBB).

The xB3 method utilizes Bioasis’ novel platform technology to administer a broad array of therapeutic agents to the brain tissue in patients who can benefit from this targeted delivery, the company said, such as those with lysosomal storage diseases.

“We are excited about the issuance of this patent by the US Patent Office because it represents a major milestone for our intellectual property protection around our core assets,” CEO Deborah Rathjen said in a statement. “Adding to the already granted patents in the U.S. and around the world, this further strengthens and reinforces our standing around our core technology and our xB3 programs.”

READ: Bioasis on a roll after Chiesi validates the power of its technology to propel drugs across the blood-brain barrier

The blood-brain barrier plays an indispensable role in protecting the brain from blood-borne disease. However, it also blocks crucial medicines from reaching the brain posing an epic challenge to treating neurological diseases.

Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing compounds into the brain. In a nutshell, the xB3 platform uses a small peptide to ferry molecules across the BBB in a process called receptor-mediated transcytosis.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Bioasis Technologies Inc.

Price: 0.25595 USD

OTCQB:BIOAF
Market: OTCQB
Market Cap: $17.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Bioasis Technologies forms 'exciting' licensing agreement with Chiesi Global...

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) CEO Deborah Rathjen tells Proactive the Canada-based firm and Italy-based Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed...

on 06/30/2020

2 min read